Xcout IntelAmplicore Inc. competitors & alternatives
The 12 closest competitors and alternatives to Amplicore Inc. among biotechnology companies — ranked by similarity to what Amplicore Inc. actually does, not by market-cap band.
Subscribe to see Amplicore Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Amplicore Inc.
Amplicore Inc. develops injectable therapeutics aimed at treating degenerative musculoskeletal disorders such as osteoarthritis, cartilage damage, degenerative disc disease, and acute meniscus tears. The company focuses on regenerative and minimally invasive approaches to address the underlying causes of joint discomfort and restore mobility for patients.
Amplicore Inc. at a glance
Amplicore Inc. is a biotechnology company headquartered in United States. Its most recent funding round, Grant, raised $5M in March 2021. Xcout tracks 8 named people at Amplicore Inc., including Felix Chang (General Counsel VP of Finance & Administration).
Amplicore Inc. leadership
- Felix ChangGeneral Counsel VP of Finance & Administration
- C. James LinFounder President & Chief Executive Officer
- James HambySenior Vice President of Business Development
- Tina ChenDirector of Clinical Affairs Pharmaceutical Project Manager
- Tyler VandivortDirector of Regulatory Affairs and Operations
- Amalia TollasAdministrative Coordinator
2 more named people on record for Amplicore Inc., with roles, board committees and tenure — see the full roster →
Amplicore Inc. funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Grant | $5M | 9 named | |
| Seed | $4M | 3 named | |
| SEC Form D filing | $2.8M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Amplicore Inc. competitors
Ranked by semantic similarity — how close each company is to Amplicore Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotechnology company
SpinalCyte is a U.S. biotechnology company developing regenerative, cell-based therapies for spinal disorders, particularly degenerative disc disease. Its work has focused on injectable allogeneic cell therapies intended to repair or regenerate damaged intervertebral discs, serving patients with spinal degeneration.
Biotech
Regentis Biomaterials Ltd. is a regenerative medicine firm dedicated to crafting innovative solutions for tissue repair, ultimately aiming to enhance patients' health and overall quality of life. The company's primary product in development is GelrinC, a novel, cell-free, ready-to-use hydrogel designed to be solidified into an implant within the knee. This implant serves to address painful knee injuries and mend articular cartilage damage. Regentis Biomaterials leverages its proprietary Gelrin platform, which employs biodegradable hydrogel implants, to develop orthopedic therapies that facilitate the regeneration of compromised or diseased tissues. The company was established in 2004 and operates from its headquarters in Herzliya, Israel.
Similar biotechnology company
Biosplice Therapeutics, Inc., formerly known as Samumed, LLC, is a private biopharmaceutical company based in San Diego, California. The company focuses on clinical developments such as pivotal trials for knee osteoarthritis.
Similar biotechnology company
Tavra Biosciences supplies cGMP-manufactured stem cell biologics, specifically bone marrow-derived mesenchymal stem cells, to licensed physicians for localized clinical use in orthopedic and regenerative medicine. The company's off-the-shelf products are manufactured in a compliant cleanroom facility and provided to support clinical practices in sports medicine and pain management.
Similar biotechnology company
Amplica Bio, Inc. is a biotechnology company that develops next-generation biologics and therapies aimed at targeting difficult diseases. The company engages in drug engineering to address challenging therapeutic targets.
Similar biotechnology company
BLOOCELL is a biotechnology company specializing in artificial tissue technology, focusing on advanced bone and cartilage repair matrix solutions.
Biotech
Aspect Biosystems develops bioengineered cellular medicines and implantable tissue therapeutics using a proprietary bioprinting platform that integrates AI, computational design, and advanced biomaterials. The company serves the biotechnology and pharmaceutical industries by creating treatments to replace, repair, or supplement biological functions for metabolic and endocrine diseases.
Biotech
Angitia Biopharmaceuticals is a clinical-stage biotechnology company focused on discovering and developing innovative therapeutics for serious musculoskeletal diseases.
Biotech
Xintela AB is a Swedish biotechnology company developing cell therapies and regenerative-medicine products based on its integrin α10 technology. Its lead program, XSTEM, uses integrin α10-selected mesenchymal stem cells for conditions such as osteoarthritis and cartilage damage, serving patients and healthcare providers through potential advanced therapies.
Biotech
BioCardia, Inc. is a pioneering clinical-stage company dedicated to regenerative medicine, focusing on the development of advanced cellular and cell-derived therapies for a range of cardiac and respiratory ailments. Central to its pipeline is the CardiAMP Cell Therapy System, designed to address heart failure and chronic myocardial ischemia. Additionally, BioCardia is advancing an allogeneic cell therapy program, also targeting cardiac and pulmonary conditions. The company is further exploring a specific allogeneic cell therapeutic platform. This investigational treatment, derived from culture-expanded mesenchymal cells sourced from bone marrow, is currently undergoing Phase I/II trials for patients suffering from ischemic systolic heart failure. Beyond its therapeutic candidates, BioCardia also provides innovative delivery solutions. These include the Helix biotherapeutic delivery system, engineered to precisely administer treatments directly into the heart muscle via an internal penetrating helical needle, and a line of Morph deflectable guides and sheaths. BioCardia maintains its headquarters in Sunnyvale, California.
Biotech
Vericel Corporation operates as a biopharmaceutical firm that has reached the commercialization phase, specializing in the research, development, production, and distribution of cell-based treatments. Its primary therapeutic areas are sports medicine and critical burn care across the United States. The company's product lineup includes MACI, an autologous cellularized scaffold employed for mending symptomatic, full-thickness cartilage damage in the knee, and Epicel, a permanent skin replacement designated as a humanitarian use device for treating deep-dermal or full-thickness burns in both adults and children. Additionally, Vericel is progressing NexoBrid, an orphan biological product currently in the registration phase, which aims to remove eschar from deep partial-thickness or full-thickness thermal burns in adults. Established in 1989 under its former name, Aastrom Biosciences, Inc., the company is headquartered in Cambridge, Massachusetts.
Similar biotechnology company
Tiger BioSciences is a medical technology company that specializes in regenerative medicine, developing cellular, acellular, and matrix-like products for wound care and aesthetic treatments. The company also manages human tissue recovery programs to supply biological materials for clinical applications. It serves healthcare providers and medical professionals globally.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Amplicore Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Amplicore Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →